Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of Iodine-131-Kab201 by intra-arterial versus intravenous administration in unresectable pancreatic ductal adenocarcinoma
ISRCTN16857581Phase 2Completed
- Sponsor
- Xenova Ltd.
- Start
- Sep 2002
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, open-label trial of KAb201 in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by Xenova Ltd. Primary endpoints: Safety, Tolerability and 1 more. Started Sep 2002; status: completed.
02
Drugs
KAb201
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on ISRCTN16857581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN16857581.